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Abstract Cyclin D1 is a cell cycle machine, a sensor of
extracellular signals and plays an important role in G1-S
phase progression. The human cyclin D1 promoter contains
multiple transcription factor binding sites such as AP-1,
NF- .B, E2F, Oct-1, and so on. The extracellular signals
functions through the signal transduction pathways con-
verging at the binding sites to active or inhibit the promoter
activity and regulate the cell cycle progression. Different
signal transduction pathways regulate the promoter at
different time to get the correct cell cycle switch. Disorder
regulation or special extracellular stimuli can result in cell
cycle out of control through the promoter activity regula-
tion. Epigenetic modifications such as DNA methylation
and histone acetylation may involved in cyclin D1
transcriptional regulation.
Keywords Promoter.Transcription factor.Signal
transduction pathway.Epigenetic regulation
Introduction
During the G1 phase, cells will response to the extracellular
signals that influence cell division, growth, and differentia-
tion. Cyclin D1 is thought to play pivotal roles in G1-S phase
transition. Mistakes in G1 phase may lead to cell cycle out of
control and cause tumorigenesis. Cyclin D1 is a sensor to
integrate extracellular signals with the cell cycle machinery,
with functions through CDK4/6 to trigger cell cycle progres-
sion. In recent years, accumulating evidence suggests cyclin
D1alsoconveycellcycle orCDK-independent functions,and
cellcan do without cyclinD1 (Coqueret 2002;F ue ta l .2004;
Lamb et al. 2003; Pestell et al. 1999).
The cyclin D1 promoter sequence was studied and
subcloned in several different laboratories (Albanese et al.
1995; Herber et al. 1994b; Motokura and Arnold 1993;
Nagata et al. 2001). The promoter sequence, GenBank
number Z29078 (Herber et al. 1994b), contains no obvious
TATA box with TF (transcription factor) binding sites such
as AP-1, SP-1, E2F, OCT-1, and so on. In this review, the
structure of cyclin D1 promoter is discussed with such
binding sites, and regulation from signal transduction
pathway converging at the binding site.
The elements of the cyclin D1 promoter
Cyclin D1 promoter popularly studied is 1,810 bp about
with many cis-elements that can mediate signals activate or
inactivate the promoter activity. From −1,309 (NFAT
binding site) to −10 (Ets binding site), there are many
regulatory elements reported. And if searching by computer
program, there are some more elements that have not yet
been studied. To compare the cyclin D1 promoter with rat
and mouse, homologues region were found (Eto 2000),
which can lead us to find new elements in human cyclin D1
promoter. The elements reviewed here only include the
elements that have been studied (Fig. 1; Table 1).
AP1
AP1sitewasidentifiedinthepromoter,whichlocatesin−954
(Albanese etal. 1999). The site may be assigned TRE (12-O-
tetradecanoylphorbol-13-acetate, TPA) response elements.
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DOI 10.1007/s13148-010-0018-yAP1 family protein, such as c-Fos, c-Jun, JunB, JunD, ATF,
Fra-1, Fra-2, and so on, can bind at this site by forming
homo- or heter-dimer (Fig. 1).
c-Jun (Albanese et al. 1995; Cicatiello et al. 2004;
Mechta et al. 1997; Soh and Weinstein 2003) Fra-1 (Burch
et al. 2004; Mechta et al. 1997) Fra-2 (Balmanno and Cook
1999) can activate cyclin D1 transcription. ATF3 (Allan et
al. 2001) activate cyclin D1 promoter activity requiring
cAMP response element-binding (CREB) site involved
although it directly bind to AP-1 site. c-Fos may sometime
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Fig. 1 Schematic representation of the elements of human cyclin D1
promoter. Elements of human cyclin D1 promoter are represented by
different colors. Detail sequences of complex motifs such as ERGE
(including AP-1, Oct-1, and YY-1) and Oct1-GAS are showed.
Sequence of Egr-1 and Sp1 are also showed. Starting site of
transcription is by two arrows due to the data of the referenced
papers, and the sequences are showed in the manuscript
elements location reference
CREB/ATF2 −58 J Biol Chem, 1999 .274(11):7341
Lef/Tcf 4 −82 J Boil Chem, 2002 .277(48):45847
Sp-1 −113, −119 J Biol Chem, 1997 .272(52):33181
Egr −137, −118 J Biol Chem, 1997 .272(52):33181
E2F −148 Mol Cell Biol, 2000. 20(2): 672
GAS −478, −144 Mol Cell Biol, 2003. 23(24): 8934–45
Oct_1 −252 Mol Cell Biol, 2003. 23(24): 8934–45
GT-boxA −494 Mol Cell, 2003.11(6):1503
CSL −525 Mol Cell Biol, 2001. 21(17): 5925
E-box −588 Epigenetics, 2009.4(7):487–99
Ets −779 Mol Biol Cell, 2001.12(12):4066
Oct_1 −941 Mol Cell Biol, 2004.24(16):7260
YY-1 −945 Mol Cell Biol, 2004.24(16):7260
AP-1 −952 Mol Cell Biol, 2004.24(16):7260
ERGE −952 Mol Cell Biol, 2004.24(16):7260
NFAT −1,309 J Biol Chem, 2009.284:36302-36311
Table 1 Positions of TF ele-
ments in human cyclin D1
promoter
Elements locations in human
cyclin D1 promoter here are nor-
malized to the paper (Motokura
and Arnold 1993)a n dm a yb e
some different to the reference
showed in the table
64 Clin Epigenet (2011) 2:63–76depress (Albanese et al. 1995) or activate (Brown et al.
1998; Cicatiello et al. 2004; Watanabe et al. 1996b) cyclin
D1 promoter. JunB usually inhibits cyclin D1 promoter and
can antagonized the c-Jun activation of cyclin D1 promoter
(Shaulian and Karin 2001). A change of AP-1 composition
toward an increase of JunB results in downregulation of
cyclin D1 (Grosch et al. 2003). So generally c-Jun is an
activator and JunB a repressor of cyclin D1 promoter. c-Fos
is expressed rapidly and transiently (Balmanno and Cook
1999), so the inhibition effect by c-Fos overexpression
(Albanese et al. 1995) probably cannot function in real cell
cycle, except for c-Fos prolonged binding by some
stimulation, e.g., oxidative stress (Burch et al. 2004).
Not only protein level but also the phosphorylated
modification status is important to AP-1 proteins. c-Jun
activation of cyclin D1 promoter requires phosphorylated
on Ser63/73-Pro motifs (Wulf et al. 2001). Phosphorylation
of JunB results in decreased JunB protein levels in mitotic
and early G1 cells. In contrast, c-Jun levels remain constant
with N-terminal phosphorylation. And the modifications of
AP-1 proteins may regulate cyclin D1 transcription tempo-
rally to control cell cycle progression (Bakiri et al. 2000).
Some TFs in addition to Ap-1 family may regulate
cyclin D1 promoter activity through AP-1 site directly
(Roche et al. 2004) or indirectly, e.g., by protein interaction
(Albanese et al. 1999), cooperation with other TF binding
sites such as CREB (Watanabe et al. 1996a).
GAS
Among the STATs, only STAT3 and STAT5 can bring about
the activation of cyclin D1 (Bromberg et al. 1999; Calo et
al. 2003; Leslie et al. 2006).
Literatures showed that activated form of STAT3 was
accompanied by increased expression levels of cyclin D1
(Bromberg et al. 1999; Kijima et al. 2002; Leslie et al.
2006; Masuda et al. 2001, 2002). And some paper showed
that STAT3 can inhibit cyclin D1expression (Zhang et al.
2003). And during the liver regeneration after partial
hepatectomy, the cyclin D1 induction was repressed, but
STAT3 was unchanged in mice (Chen et al. 2004), which
may suggest that modification of STAT3 is important to its
activity. Data also showed cyclin D1 overexpression and
STAT3 activation were, mutually exclusive events in MM
(Quintanilla-Martinez et al. 2003).
But there was no evidence showing STAT3 can directly
function through the cyclin D1 promoter, lacking data such
as EMSA, ChIP and so on (Masuda et al. 2001, 2002).
Moreover, cyclin D1 repression may due to CDKN1A or
CDKN1B promoter induction. There are some evidences
shows that STAT3 can active CDKN1B or CDKN1A
promoter through PI3K pathway. Clearly, PI3K pathway
can induce cyclin D1 promoter, and new evidences
(Bienvenu et al. 2005) show that cyclin D1 is recruited to
the CDKN1A promoter by a STAT3-NcoA complex
leading to an inhibition of the p21waf1 gene (Bienvenu et
al. 2005). In conclusion, in some context STAT3 and cyclin
D1 balanced in cell cycle regulation but generally the
relation between cyclin D1 and STAT3 may due to cell type
and now is unclear.
Unlike STAT3, STAT5 can directly bind cyclin D1 promoter
inwhichtherearetwoSTATbindingsites,onecalledGAS1the
other is GAS2 (Magne et al. 2003) .T h eG A S 1s i t e( d i s t a l )c a n
bind stat5a/b which can activate cyclin D1 promoter
(Brockman et al. 2002; Magne et al. 2003; Matsumura et al.
1999).The phosphorylated modification of STAT5b at Tyr679
induces STAT5b activation and then activate cyclin D1
promoter through interaction with other transcription factors,
such as LEF1 and CREB/ATF2 (Kabotyanski and Rosen
2003). STAT5a lacks the Tyr679 site which can explain why
only STAT5a/5b heterdimer or STAT5b/5b homodimer but
not STAT5a/5a homodimer bind to the cyclin D1 promoter
(Magne et al. 2003). Unlike GAS1, the GAS2 site, accurately
composite Oct-GAS element, may be masked by Oct-1
protein which binding site overlap with GAS2. The binding
of STAT5 to this site is required both GAS2 and OCT-1
element, with the interaction between STAT and PAU domain
of Oct-1 (Magne et al. 2003).
E2F
The E2F binding sites in cyclin D1 promoter illustrate Fig. 1.
Among five members of the E2F family, including E2F1, 2,
3, 4, and 5, only E2F1and E2F4 can bind this promoter
(Watanabe et al. 1998). E2F transcription factors are bound
to RB protein, and when RB is phosphalated by cyclin D1/
CDK4, 6, E2Fs are released free. The free E2Fs then
regulate their target genes promoting cell cycle progression.
Cyclin D1/CDK4, 6, RB and E2F cooperate together to
enter cell cycle and progression in normal cell or to be
transformed in tumor cell lines. Although cyclin D1 is
upstream upon E2F protein during cell cycle, there are three
feedbacks loop between cyclin D1 and E2F to facilitate the
progression. E2F4 expresses at early G1 phase (Muller et
al. 1997) which can activate cyclin D1 and results in more
E2F4 protein level. This is a positive feedback loop, which
occurs at early phase of cell cycle and let cell enter cell
cycle quickly. There are also two other feedback loops,
which respectively result in cell cycle arrest or progression
depending cell types. E2F4 and E2F1 are functionally
different which also express at different time in cell cycle
(Muller et al. 1997). Contrast to E2F4, E2F1 expresses at
late G1 phase (Muller et al. 1997). E2F1 regulates a set of
genes that can let cell cycle progression. Depending
different cell context, E2F1 can activate (Inoshita et al.
1999)o rd e p r e s s( W a t a n a b ee ta l .1998) cyclin D1
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proliferation then apoptosis (Knezevic and Brash 2004).
Transgenetic mice expressing high level E2F1 also induce
apoptosis (Pierce et al. 1998a). In this context, free E2F1
can depress cyclin D1, which formed a negative feedback
loop to avoid apoptosis (Watanabe et al. 1998). The last
feedback loop is that free E2F1 proteins can active cyclin
D1 (Fan and Bertino 1997). The high level free E2F1
protein can activate another set of genes, e.g., FGFR which
let cell cycle progression or transformed cells (Tashiro et al.
2003). The affinity of E2F1 to cyclin D1 promoter is higher
than E2F4 (Lee et al. 2000). E2F1 has more potent activator
activity than E2F4 (Pierce et al. 1998b). E2F-4 is located in
nucleus from G0 until mid-G1 phase and mainly cytoplas-
mic in late G1, S, and G2 phases. In contrast, endogenous
E2F-1 is absent from resting cells and is predominantly
nuclear in late G1 and S (Muller et al. 1997). Due to the
different affinity, at early stage E2F4 bounding that induce
cell cycle entrance, and at late stage E2F1 take place of
E2F4 results in cell cycle progression or transformation.
When depression of cyclin D1 promoter by E2F1, the
SP1/2/3 is needed (Watanabe et al. 1998). Sp1 is inducible
in early–mid-G1 phase (Nagata et al. 2001). In conclusion,
E2F4 activate cyclin D1 promoter whereas E2F1 can
activate or depress cyclin D1 promoter due to cell context.
NF- .B
NF- .B contributes to cell cycle progression, and one of
its targets might be cyclin D1in T47D cell (Hinz et al.
1999). Dbl and Dbs regulated transcription from the
cyclin D1 promoter in a NF- .B-dependent manner
(Whitehead et al. 1999). Examination of the sequence
from the human cyclin D1 promoter identified potential
NF-.B-binding sites at positions −858, −749, and −39
that matched the NF-.B consensus binding sequence,
GGG(G/A)NNYYCC (Guttridge et al. 1999). Different
NF-.B complex members, p65 p50 and p52, can bind
these sites (Guttridge et al. 1999; Westerheide et al. 2001).
Although there are three NF- .B-binding sites, only the
proximal site (−39) may be functional (Guo et al. 2009).
Generally NF-.B binding can induce cyclin D1 pro-
moter(Joyce et al. 1999), whereas PKC delta depress cyclin
D1 through NF-.B binding to −39 site (Page et al. 2002).
Bcl-3, a co-activator with NF-.B p52 homodimers, was
demonstrated to directly activate the cyclin D1 promoter
through an NF-.B binding site (Westerheide et al. 2001),
whereas p53 represses cyclin D1 transcription through this
site under UV treatment downregulating of Bcl-3 (Rocha et
al. 2003). Data also showed p53 can inhibit cyclin D1
promoter under heat shock (Guo et al. 2009). So stress
stimulations may depress cyclin D1 through the proximal
NF-.B binding site.
CREB/ATF2
The cAMP can inhibit or induce cell cycle progression and
cyclin D1 expression. The CRE/ATF2 binding consensus site
in cyclin D1 promoter locates at −57 (D’Amico et al. 2000;
Lee et al. 1999;M u s ae ta l .1999; Watanabe et al. 1996a),
which can bind CRE/ATF2 (D’Amico et al. 2000; Lee et al.
1999; McMahon et al. 1999;M u s ae ta l .1999), c-Jun (ATF-
2/c-Jun heterodimers; Sabbah et al. 1999), CREM1 (Page et
al. 2002), ATF1 (Schneider et al. 2002), and c-Fos (Brown et
al. 1998). The effecter of Wnt signal transduction pathway,
β-catenin/Tcf4, can also bind this site to induce cyclin D1
promoter (Pradeep et al. 2004). Galectin-3 (Lin et al. 2002)
and G-17 (Pradeep et al. 2004) induces the cyclin D1
promoter also via the CREB site. Cyclosporine effective
element overlaps the element and confers cyclosporine
sensitivity to the cyclin D1 promoter (Schneider et al.
2002). PPAR gamma2 (Sharma et al. 2004), PKCdelta (Page
et al. 2002) and p16INK4a (D’Amico et al. 2004) can inhibit
cyclin D1 promoter through this site.
CREB Ser 133 phosphorylation is necessary for induc-
tion of cyclin D1 promoter through this site (D’Amico et al.
2000; Lee et al. 1999; Sharma et al. 2004), but the POU
domain of oct-1 can potent its activation without Ser 133
phosphorylation by protein interaction (Boulon et al. 2002).
But CREB Ser 133 phosphorylation may result in repres-
sion of cyclin D1 due to cell type (Musa et al. 1999).
TCF4
Nuclear β-catenin expression was correlated with cyclin D1
overexpression (Saito et al. 2001; Shtutman et al. 1999;
Utsunomiya et al. 2001) with promoting malignant trans-
formation by triggering cyclin D1 expression (Behrens
2000; Brabletz et al. 1999, 2000, Graham and Asthagiri
2004; Jung et al. 2004; Lepourcelet et al. 2004; Morin
1999; Muller-Tidow et al. 2004). TCF4 (Graham and
Asthagiri 2004) and β-catenin (Shtutman et al. 1999)
activate the cyclin D1 promote via the consensus TCF/
LEF-binding sites (Grueneberg et al. 2003; Holnthoner et
al. 2002; Tetsu and McCormick 1999). In addition to TCF4
mainly (Gotoh et al. 2003), LEF-1 (Grueneberg et al. 2003),
HBP1 (Sampson et al. 2001), and UBF2 (Grueneberg et al.
2003) can also affect the cyclin D1 promoter activity by
interaction with β-catenin or LEF-1.
β-catenin is a key component in the canonical Wnt
pathway (D’Amico et al. 2000). Some molecules in addition
to wnt, such as IKKα (Albanese et al. 2003), PTEN (Persad
et al. 2001b), and SOX17 (Lange et al. 2009) can also
regulate it. In addition to Wnt pathway, PI3k signal
transduction pathway (Albanese et al. 2003;D ’Amico et al.
2000), ILK (D’Amico et al. 2000;P e r s a de ta l .2001b), RA
(Shah et al. 2002), caveolin-1 (Hulit et al. 2000) can also
66 Clin Epigenet (2011) 2:63–76regulate cyclin D1 promoter activity via consensus this site
in cyclin D1 promoter, and CREB site (Pradeep et al. 2004)
may be needed.
E box
There is an E box element at −558 in human cyclin D1
promoter (Eto 2000; Magne et al. 2003; Zhang et al. 2002).
The E box can bind Myc or other transcription factor, so
some paper may assigned it c-myc element. Myc proteins
bind to cyclin D1 promoter to inhibit its activity (Chien et al.
2008; Gonzalez-Mariscal et al. 2009; Philipp et al. 1994),
probably inducing DNA methylation (Hervouet et al. 2009).
The element may activate cyclin D1 promoter by different
protein interaction with myc, e.g., Max (Yang et al. 2009).
Ets
In the proximal region of cyclin D1 promoter, an Ets (c-Ets2)
site was first identified in 1995 (Albanese et al. 1995). There
several putative Ets binding site in cyclin D1 promoter. Tetsu
and McCormick (1999) demonstrated four other Ets sites
which they named Ets A B C D, but only the B box is
mediated by P21RAS. Zhao et al. (2001)d e m o n s t r a t e dt h a t
the EtsB binding site mediated cyclin D1 promoter regula-
tion by FAK. The proximal box can mediated PKC delta
activity (Page et al. 2002), and RAS induced MAPK signal
transduction (Albanese et al. 1995).
CSL
Notch, an evolution-conserved membrane crossed-signal
molecular (for review, see Artavanis-Tsakonas et al.
1999) encoding a family of transmembrane proteins that
are involved in many cellular processes such as differen-
tiation, proliferation, and apoptosis, can activated cyclin
D1 promoter transcription through a CSL site (Jeffries et
al. 2002; Ronchini and Capobianco 2001;S t a h le ta l .
2006).
GT box
There are four GT box in cyclin D1 promoter but only the GT
box A was active which was responsible for the inhibition
effect of KLF8 to cyclin D1 promoter (Zhao et al. 2003).
Egr-1
In cyclin D1 promoter,Egr-1 site which overlaps two sp1
sites, can mediate TGFβ (Yan et al. 1997) and Ang II
(Guillemot et al. 2001)-induced cyclin D1 upregulation. But
unexpectedly the Egr-1 binding activity to the cyclin D1
promoter is not influenced by SP1 binding (Yan et al. 1997).
Sp1
The transcription factor SP1 is a DNA-binding protein
which interacts with a variety of gene promoters containing
GC-box elements. Among many possible SP1 sites, the site
studied in the promoter overlaps with Egr-1. Induction of
the cyclin D1 promoter activity in the early to mid G 1
phase is via the SP1 sites by the Ras-dependent pathway
(Nagata et al. 2001). NeuT can induce cyclin D1 promoter
by Sp1/3 binding in cooperation with E2F site (Lee et al.
2000). In PC12 cells NGF can induce neurite outgrowth
and cyclin D1 transcription via Sp1 and NF- .B binding
site in the proximal region of the cyclin D1 promoter
(Marampon et al. 2008).
CycY
The motif is SP1-like but bind basic transcription element
binding factor (BTEB) whose molecular weight is smaller
than SP1 (Hsiang and Straus 2002).But binding BTEB on
CycY site is not responsible for cyclopentenon (Hsiang and
Straus 2002).
ARE
p19ARF repressed cyclin D1 through a novel distal cis-
element ARE at −1137, which bound p53 revealed by
chromatin-immunoprecipitation assays (D’Amico et al.
2004). P53 can also repress cyclin D1 promoter in −39
NF-.B site and HADC1 may involved (Guo et al. 2009;
Rocha et al. 2003).
Complex motif
Complex motif here means that two elements in a promoter
are very close, sometimes joined together. In this promoter,
e.g., E2F and sp1, stat and oct-1 are close to form complex
motifs. More often, the proteins that bound to complex
motif could interact with each other. So we can deduce that
proteins which can interact with each other may result in
DNA sequence rearrangement. The protein and DNA
sequence can co-evolve.
Starting site
Different groups studied the transcription star site with different
methods (Herber et al. 1994a; Hsiang and Straus 2002;
Motokura and Arnold 1993; Philipp et al. 1994). Among
these, CCTCCAGAGGGCTGT (Motokura and Arnold 1993)
and CCTCCAGAGGGCTGT (Hsiang and Straus 2002;
transcription star site is underlined) were prevalently accepted.
In this review, elements positions were normalized to
CCTCCAGAGGGCTGT (Motokura and Arnold 1993).
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There are mainly three signal transduction pathways involved
in cyclin D1 promoter regulation, which are MAPK, PI3K/
Akt, and Wnt. Others such as ER, NF-κB, JAK/STAT, Rac1/
NADPH oxidase are also involved. Here, wediscuss the main
three pathways: MAPK, PI3K/Akt and Wnt including its
molecules, response elements and cross-talk points (Fig. 2).
ERK1/2 cascade can activted cyclin D1 promoter
activity. Raf/Mek/Erk pathway usually activates cyclin D1
promoter (Chu et al. 2005; Greulich and Erikson 1998;
Page et al. 1999a, b; Ramakrishnan et al. 1998; Watanabe et
al. 1996a, b; Weber et al. 1997a, b). There are two phases
of ERK activation, of which the second sustained phase is
required for activation of cyclin D1 promoter (Fassett et al.
2003; Talarmin et al. 1999; Treinies et al. 1999; Weber et
al. 1997b). But the prolonged ERK activation results in
downregulation cyclin D1 due to inhibition of CREB
activity, including its DNA binding ability and Ser-133
phosphorylation (Wang et al. 2003), or due to ERK nuclear
location (Burch et al. 2004; Clark et al. 2004). P38 usually
inhibits (Catalano et al. 2004; Ellinger-Ziegelbauer et al.
1999; Kintscher et al. 2003; Lavoie et al. 1996; Lee et al.
1999; Page et al. 2001; Pruitt et al. 2002; Todd et al. 2004;
Westwick et al. 1998) and sometimes activated (Klein et al.
2003; Lee et al. 2000, 1999; Recio and Merlino 2002)
cyclin D1.SV 40 small antigen can induce cyclin D1
promoter by ERK and SAPK pathway (Watanabe et al.
1996a). JNK can activate cyclin D1 promoter via activating
c-jun (Oktay et al. 1999; Wulf et al. 2001) and ATF2, which
can by binding CREB/ATF2 site (Lee et al. 1999). But
some literatures reported JNK also inhibited cyclin D1
promoter (Grosch et al. 2003) or had no function on cyclin
D1 expression in bovine tracheal myocytes (Page et al.
1999a).
ERK pathway induces cyclin D1 promoter by Ets or AP-
1( C h ue ta l .2005) elements in cyclin D1 promoter
(Albanese et al. 1995; Chu et al. 2005; Guillemot et al.
2001). V-src activation of cyclin D1 involved the ERK,
p38, and JNK via CREB site (Lee et al. 1999), but in
CCL39 cells, ERK5 but not the ERK1/2 cascade regulate
cyclin D1 promoter via this site (Mulloy et al. 2003).
The Wnt signaling pathway is conserved in various
organisms from worms to mammals, and plays important
roles in development, cellular proliferation, and differenti-
ation. Wnt stabilizes cytoplasmic β-catenin and then β-
catenin is translocated into the nucleus where it stimulates
the expression of genes including cyclin D1 (Kikuchi 2000;
Shtutman et al. 1999; Tetsu and McCormick 1999). PI3k/
Akt signal transduction pathway can inhibit GSK3β and
then promote β-catenin to activate cyclin D1 promoter via
the TCF site (Albanese et al. 2003). PI3k/Akt signal
transduction pathway can also activate cyclin D1 promoter
by modulating CREB via its binding site. But this may be
weaker than that by inhibition of GSK3β (Xie et al. 2003).
ILK and PDK1 can activate Akt by phasphation at different
amino acid site, ser-473 and ser-308, respectively (Persad et
al. 2001a), which all take part in Akt activation which
consequently then inhibits GSK3β at ser-9 (Troussard et al.
2003). In some cell type, PKC but not Akt can inhibit
GS3Kβ (Xie et al. 2003). Rac1 which can form positive
regulation loop with PI3k (Welch et al. 2003), can activate
cyclin D1 by NF-.B (Joyce et al. 1999) and CREB site
(Bauerfeld et al. 2001; Joyce et al. 1999; Page et al. 2000)
independent of ERK (Page et al. 1999b, 2000). Wnt
pathway regulation whereby activation of Rac1 amplifies
the signaling activity of stabilized/mutated β-catenin by
promoting its accumulation in the nucleus, and synergizing
with β-catenin to augment TCF/LEF-dependent gene
transcription (Esufali and Bapat 2004). PI3k/Akt signal
transduction pathway plays important role in regulation of
cyclin D1 promoter. The pathway may induce cyclin D1 by
CREB site in the promoter and can modulate GSK3β to
activate β-catenin, which can induce cyclin D1. There are
many interlinks between PI3k and wnt pathway in
regulation of cyclin D1 promoter.
It is usually thought that MAPK, unlike wnt, distinct
from PI3k signal transduction pathway (Page et al. 2000),
but there are still many cross-talks between them. The ERK
pathway modulated AKT phosphorylation by acting on the
PTEN levels (Marino et al. 2003). Persad et al. (2001b)
define a pathway that ILK and GSK-3 can regulate β-
catenin stability, nuclear β-catenin expression, and its
transcriptional activity. Wnt-transactivated ErbB1 was
responsible for MAPK activation and the increased levels
AP-1 LEF/TCF CREB/ATF2 Ets
Raf
MEK
ERK
 -catenin
Wnt
GSK3
PI3k
PKB/
Akt
PKC(?) PTEN
β
β
Fig. 2 The main three signal transduction pathways on human cyclin
D1 promoter. Three pathways are MAPK, PI3k/Akt, and Wnt. MAPK
pathways regulate cyclin D1 promoter via AP-1 and Ets elements.
Elements such as LEF/TCF and CRE are responsible for PI3k/Akt and
Wnt pathways and GSK3β is their cross-talk point. PETN can cross-
talk between MAPK and PI3k/Akt pathway
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(Civenni et al. 2003). TGF-β1 also first decreases and later
potentiates the levels of EGF-activated MEK1/MAPK and
PKB, which results in initially suppresses EGF-induced
cyclin D1 expression then later releases the inhibition (Yan
et al. 2000) implying there are other cross-talks between
MAPK and PI3k/Akt.
Taken together, there are cross-talks between Wnt and
PI3k usually converging at GSK3β. MAPK pathway is
generally distinct from PI3k, but they can cross-talk, e.g.,
by PTEN (Marino et al. 2003; Weng et al. 2001), TGF-β1
(Yan et al. 2000), PAK (Nheu et al. 2004), or others. PTEN
is also involved in the regulation of nuclear β-catenin
accumulation and TCF transcriptional activation in an
APC-independent manner (Persad et al. 2001b). Sometimes
in the mammary gland Wnt pathway can activate cyclin D1
by MAPK activation (Civenni et al. 2003).
The temporal expression of cyclin D1
Cell cycle progression requires different signal molecules
function at the right time. The stimulation from growth factor
is temporal, biphasic (Jones and Kazlauskas 2001). So what
pathway function at what time is critical for cell cycle
progression. Rac/Cdc42 signaling induces cyclin D1 expres-
sion in an early G1 phase. In the mid-G1 phase, cyclin D1 is
induced by sustained ERK, which can be promoted by Rho
kinase. At the same time, Rho kinase suppresses Rac/Cdc42
activity (Roovers and Assoian 2003; Roovers et al. 2003;
Welsh et al. 2001). MKP, as an inhibitor of ERK, can form a
feedback loop to a flexibly balanced ERK activity (Bennett
and Tonks 1997; Bhalla et al. 2002; Ryser et al. 2004). MKP
overexpression can result in downregulation of cyclin D1
(Kawanaka et al. 2001;L a v o i ee ta l .1996; Qin et al. 2005).
In the later stages of G1, PI3k pathways instead of ERK to
sustain cyclin D1 expression to perform S phase entry (Gille
and Downward 1999;M a r i n oe ta l .2003). Akt/PKB, an
important downstream of PI3k, is expressed in late G1phase
(Gille and Downward 1999; Paramio et al. 1999), but it only
influences partly cyclin D1 expression (Gille and Downward
1999). So there may be multiple signal molecules involved.
Epigenetic regulation of the cyclin D1 transcription
Epigenetic regulation means a heritable alteration in gene
expression without the primary DNA sequence changing.
The major mechanisms involved in epigenetic changes are
modification of DNA and histone protein such as DNA
methylation at cytosine bases and histone acetylation.
Epigenetic modification sites involved in cyclin D1
transcriptional regulation include (1) GC-rich Sp1/CRE
binding site, (2) remote upstream region mainly in
chromosome translocation, a common cause of blood
tumor, (3) 1 kb upstream including E-box element, and
(4) other DNA methylation sites which have not been
studied. Actually, function of DNA methylation and histone
modification are commonly studied together.
DNA methylation at Sp1/CRE binding sites of rat cyclin
D1 promoter may be essential for keeping a number of the
stromal cells in the basal layer live (Kitazawa et al. 1999). In
hamster cell, using human cyclin D1 promoter, data showed
that DNA methylation was found at Sp1/CRE binding sites
(Hilton et al. 2005). However, the epigenetic modification
including DNA methylation at cytosine bases and H3/H4
acetylation at Sp1/CRE binding sites may not be essential for
transcriptional regulation of cyclin D1 (Krieger et al. 2005).
Chromosome translocation, a common cause of blood tumor,
is thought to transcriptional regulation of cyclin D1. Data
showed that such epigenetic modifications mainly were
found in the translocation region, distal upstream region of
cyclin D1 promoter (120 kb from the transcriptional start
site; Liu et al. 2004) and demethylation may due to CTCF
and NPM (Liu et al. 2008a). Different group found the DNA
methylation or histone acetylation in this region from
different blood tumor including MCL, MM, and NHL and
so on. Although the epigenetic modification may be essential
in gene transcriptional regulation, it was thought that the
epigenetic modification have no effect on cyclin D1
transcription. No DNA methylation was found in cyclin D1
promoter by genomewide methylation analysis in MCL
patients (Leshchenko et al. 2010). The endogenous cyclin
D1 promoter may be inaccessible to the transcription factor
and cyclin D1 transcription may be control through other
different manner. Actually the MYEOV gene which located
approach to cyclin D1 was transregulated by this epigenetic
modification (Janssen et al. 2002), which showed that
epigenetic regulation may need a proper transcriptional
status. Interestingly, in some MM and MCL samples that
did not express cyclin D1, the cyclin D1 promoter was
hypomethylated and hyperacetylated, which suggested that
DNA methylation in the promoter may be related to
malignant phase rather than to cyclin D1 regulation (Liu et
al. 2004). And this agreed with the data in NHL research, in
which the DNA methylation was identified as a tumor
maker, although it is not involved in cyclin D1 transcription
(Shi et al. 2007), which showed that the region was proven
to be methylated. Genes other than cyclin D1 may be
regulated by DNA methylation which can then regulated
cylcin D1 including CDKN2A (Vonlanthen et al. 1998;
Kawauchi et al. 2004; Takahira et al. 2004;H u t t e re ta l .
2006; Liu et al. 2008b;M a t s u d a2008; Takahira et al. 2004;
Kawauchi et al. 2004;H a s h i g u c h ie ta l .2001;H u t t e re ta l .
2006; Dominguez et al. 2002), wnt (Fox et al. 2008;M a r t i n
et al. 2009), and miRNA (Ilnytskyy et al. 2008). Data from
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upstream from transcription start site may not affect cyclin
D1 transcription (Liu et al. 2004). Although data from blood
tumor cell mainly showed that epigenetic modification may
not involved in cyclin D1 transcription, in glioma cells
Hhervouet et al. (2009) showed a DNA methylation
mechanism in depression of cyclin D1 transcription via E-
box, a site-specific DNA methylation site in the 1 kb
upstream region of cyclin D1.And different from blood
tumor research which showed treatment of TSA or 5-Aza
had no effect on cyclin D1 transcription (Krieger et al.
2005), data showed that the epigenetic regent can regulate its
transcription or translation in glioma cell,H1299 cell,
follicular lymphoma (also blood tumor) cell and MCF-7 cell
(Alao 2007;A l a oe ta l .2006a, b; Bennett et al. 2009;
Hervouet et al. 2009; Rocha et al. 2003). Data from HCC
(primary liver cancer) showed DNA methylation in cyclin
D1 promoter (Matsuda 2008) and in lung cancer, DNA
methylation of CDKN2A promoter in regulation of cyclin
D1 may be different (Zhou et al. 2001). So epigenetic
regulation may be different due to cell types. Other than
histone acetylation, histone methylation of H3k9 may inhibit
human (Krieger et al. 2005) and mouse (Shirato et al. 2009)
cyclin D1 transcription, and this may function in develop-
ment (Ait-Si-Ali et al. 2004). Considering CpG islands
identifying, other sites may be studied to reveal the
epigenetic regulation mechanism involved in cyclin D1 for
example there are many other CpG inlands (Krieger et al.
2005) except for the region mentioned above.
In conclusion, epigenetic modification (DNA methyla-
tion and histone modification) involved in cyclin D1
transcriptional regulation may be cell type-specific. In most
blood tumor, cyclin D1 transcription is not due to DNA or
histone modification, but this was not the barrier for the
DNA methylation to be used as a putative tumor marker.
Other gene (especially CDKN2A) may be regulated by
epigenetic modification. There may be other epigenetic
modification which can be studied to provide insight into a
new mechanism of epigenetic transcriptional regulation of
cyclin D1, for there are other CpG islands not studied yet.
Conclusion
Cell cycle control is complex, in which cyclin D1
transcription regulation may be important. But firstly, cell
cycle control is not only in transcription level but also in
post-transcriptionally regulated manner, e.g., protein degra-
dation, modification, which all play an important role in
cell cycle control. For example, GSK3β can also increases
cyclin D1 protein degradation (Hamelers et al. 2002;
Jirmanova et al. 2002; Kim et al. 2002; Zou et al. 2004),
and cyclin D1 mRNA half-life becomes shorter when
serum is removed (Guo et al. 2005). And secondly, much
study got from synchronized cell by serum deprivation,
which cannot reflect the real cycle. In actively cycling cells,
cyclin D1 may be induced to high levels in G2 phase, and
the expression levels of cyclin D1 in G2 phase determine
the fate of the next cell cycle (Guo et al. 2005; Stacey
2003). Thirdly, some cell can proliferfy and organ devel-
oped without cyclin D1 (Kozar et al. 2004; Malumbres et
al. 2004). Taken together, the regulation of cyclin D1
promoter is important in cell cycle control, but it is not all.
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